Document Detail

Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation.
MedLine Citation:
PMID:  23162092     Owner:  NLM     Status:  MEDLINE    
CONTEXT: The current survey study investigated the recurrence rate of hyperprolactinemia after cabergoline (CAB)-induced pregnancy and after lactation as well as safety of CAB exposure during early gestation.
PATIENTS AND METHODS: From 1997-2008, 143 pregnancies were recorded in 91 patients with hyperprolactinemia (age 30.4 ± 4.7 yr, 76 microadenomas, 10 macroadenomas, and five nontumoral hyperprolactinemia). CAB therapy was discontinued within wk 6 of gestation in all. Pregnancies were monitored until delivery or termination, during and after lactation, twice yearly up to 60 months. The incidence of abortions, premature delivery, and fetal malformations was also analyzed.
RESULTS: Pregnancies resulted in 13 (9.1%) spontaneous abortions and 126 (88.1%) live births. No neonatal malformations and/or abnormalities were recorded. In 29 of 91 patients (three with macroadenomas), treatment with CAB had to be restarted within 6 months after lactation because of hyperprolactinemia recurrence, whereas in 68% of cases, no additional therapy was required up to 60 months. No tumor mass enlargement was observed. All patients but three were breastfeeding, 35 (38.5%) for less than 2 months and 56 (61.5%) for 2-6 months. Three months after cessation of lactation and 60 months after pregnancy, no difference in prolactin levels was found between patients nursing for less than 2 months and 2-6 months.
CONCLUSIONS: Fetal exposure to CAB at conception does not induce any increased risk of miscarriage or malformations. Pregnancy is associated with normalization of prolactin levels in 68% of patients. Breastfeeding does not increase the recurrence rate of hyperprolactinemia.
Renata S Auriemma; Ylenia Perone; Antonella Di Sarno; Ludovica F S Grasso; Ermelinda Guerra; Maurizio Gasperi; Rosario Pivonello; Annamaria Colao
Publication Detail:
Type:  Evaluation Studies; Journal Article     Date:  2012-11-16
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  98     ISSN:  1945-7197     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-07     Completed Date:  2013-03-07     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  372-9     Citation Subset:  AIM; IM    
Department of Molecular and Clinical Endocrinology and Oncology, Federico II University, via S. Pansini 5, I-80131 Napoli, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects,  therapeutic use
Breast Feeding
Data Collection
Dopamine Agonists / adverse effects,  therapeutic use
Ergolines / adverse effects,  therapeutic use
Hyperprolactinemia / complications,  drug therapy,  epidemiology*,  etiology
Infertility, Female / drug therapy,  epidemiology,  etiology
Lactation* / blood,  physiology
Pituitary Neoplasms / complications,  drug therapy,  epidemiology
Pregnancy Complications, Neoplastic / drug therapy,  epidemiology,  etiology
Pregnancy Outcome / epidemiology
Prolactinoma / complications,  drug therapy,  epidemiology
Puerperal Disorders / epidemiology*,  etiology
Time Factors
Reg. No./Substance:
0/Antineoplastic Agents; 0/Dopamine Agonists; 0/Ergolines; LL60K9J05T/cabergoline

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5?-Reductase, Explaining the N...
Next Document:  Inverse Relationship between Serum Osteocalcin Levels and Visceral Fat Area in Chinese Men.